Bibliography

Export 6387 results:
Filters: First Letter Of Keyword is P  [Clear All Filters]
M
McGregor A.L, Hoque M.R, Nickel S., Smith A.J, Atiquzzaman M..  2022.  Anti-Epileptic Medication Exposure Influences Functional Status in New Zealand Stroke Patients: A Retrospective Population-Level Study. Drugs - Real World Outcomes. 9(1):165-173.
McGregor A.L, Hoque M.R, Nickel S., Smith A.J, Atiquzzaman M..  2022.  Anti-Epileptic Medication Exposure Influences Functional Status in New Zealand Stroke Patients: A Retrospective Population-Level Study. Drugs - Real World Outcomes. 9(1):165-173.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.
Matlow J.N, Bronskill S.E, Gruneir A., Bell C.M, Stall N.M, Herrmann N., Seitz D.P, Gill S.S, Austin P.C, Fischer H.D et al..  2017.  Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 65(7):1535-1542.
Matlow J.N, Bronskill S.E, Gruneir A., Bell C.M, Stall N.M, Herrmann N., Seitz D.P, Gill S.S, Austin P.C, Fischer H.D et al..  2017.  Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 65(7):1535-1542.
Matlow J.N, Bronskill S.E, Gruneir A., Bell C.M, Stall N.M, Herrmann N., Seitz D.P, Gill S.S, Austin P.C, Fischer H.D et al..  2017.  Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. Journal of the American Geriatrics Society. 65(7):1535-1542.
Maxwell C.J, Campitelli M.A, Hogan D.B, Diong C., Austin P.C, Amuah J.E, Lapane K., Seitz D.P, Gill S.S, Gruneir A. et al..  2017.  Frailty, antipsychotics and mortality among community-based older adults with impaired cognition. Pharmacoepidemiology and Drug Safety. 26(Supplement 2):456-457.